Abstract Number: 0148 • ACR Convergence 2020
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
Background/Purpose: Physicians often consider adverse events when choosing therapies for PsA and RA but may give less attention to other ways in which treatments affect…Abstract Number: 0258 • ACR Convergence 2020
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
Background/Purpose: Because systemic lupus erythematosus (SLE) is a complex and heterogeneous disease, we have developed a conceptual model that divides SLE activity into two dimensions:…Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…Abstract Number: 0921 • ACR Convergence 2020
The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Background/Purpose: The Hospital Anxiety and Depression Scale (HADS) is a screening tool used in patients with different medical conditions. However, its validity, reliability and responsiveness…Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…Abstract Number: 1615 • ACR Convergence 2020
Assessing Preparation for Care Transition Among Adolescents with Rheumatologic Disease: A Quality Assessment with Patient Survey
Background/Purpose: Despite the risk for poor outcomes and gaps in care in the transition from pediatric to adult care, most pediatric rheumatology centers lack formal…Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…Abstract Number: 0149 • ACR Convergence 2020
How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?
Background/Purpose: At RA onset, DMARDs are essential to controlling inflammation and preventing disability. In people with established RA, specific beliefs about the necessity of DMARDs…Abstract Number: 0265 • ACR Convergence 2020
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
Background/Purpose: Multiple indices are available to measure disease activity in SLE patients, but are often considered too complex and time consuming for use in routine…Abstract Number: 0464 • ACR Convergence 2020
Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study
Background/Purpose: The COVID-19 pandemic is an unprecedented public health crisis affecting people worldwide, including those with rheumatic and musculoskeletal diseases (RMDS). REUMAVID aims to assess…Abstract Number: 0941 • ACR Convergence 2020
MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
Background/Purpose: RAPID3 (routine assessment of patient index data) on an MDHAQ (multiple multidimensional health assessment questionnaire) was developed initially to assess patients with rheumatoid arthritis…Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 43
- Next Page »